Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

NCT02719990 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
36
Enrollment
INDUSTRY
Sponsor class

Stopped Phase 3 clinical trial of somavaratan in pediatric growth hormone deficiency (PGHD) did not meet its primary endpoint of non-inferiority.

Conditions

Interventions

Sponsor

Versartis Inc.